<code id='3CD2736B82'></code><style id='3CD2736B82'></style>
    • <acronym id='3CD2736B82'></acronym>
      <center id='3CD2736B82'><center id='3CD2736B82'><tfoot id='3CD2736B82'></tfoot></center><abbr id='3CD2736B82'><dir id='3CD2736B82'><tfoot id='3CD2736B82'></tfoot><noframes id='3CD2736B82'>

    • <optgroup id='3CD2736B82'><strike id='3CD2736B82'><sup id='3CD2736B82'></sup></strike><code id='3CD2736B82'></code></optgroup>
        1. <b id='3CD2736B82'><label id='3CD2736B82'><select id='3CD2736B82'><dt id='3CD2736B82'><span id='3CD2736B82'></span></dt></select></label></b><u id='3CD2736B82'></u>
          <i id='3CD2736B82'><strike id='3CD2736B82'><tt id='3CD2736B82'><pre id='3CD2736B82'></pre></tt></strike></i>

          Home / entertainment / entertainment

          entertainment


          entertainment

          author:Wikipedia    Page View:2
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In